盘龙药业：荣膺天马奖优秀团队奖 卓越投关沟通赢得市场信任

Core Viewpoint - Panlong Pharmaceutical has been recognized for its excellence in investor relations management, winning the "Outstanding Investor Relations Management Team Award" at the 16th Tianma Awards, reflecting the capital market's high regard for the company's governance structure and investor relations efforts [1][5] Financial Performance - In 2024, Panlong Pharmaceutical achieved a profit of 137 million yuan, representing a year-on-year increase of 5.96%, with net profit attributable to shareholders reaching 120 million yuan, up 8.91% [3] - The company continued its growth momentum into the first quarter of 2025, with operating revenue increasing by 19.08% year-on-year and profit rising by 18.14%, showcasing operational stability [3] - Over the past eight years since its listing, Panlong Pharmaceutical has maintained continuous profit growth, which is fundamental to building long-term investor trust [3] Product and R&D Strategy - The company focuses on the "rheumatism and bone disease, chronic pain" sector, employing a research and development strategy that combines market orientation with innovation [4] - Panlong Pharmaceutical is developing new products such as PLJT-001, PLJT-002, PLJT-003, and PLJT-004, and is enhancing its product pipeline through a "1+N" large R&D system [4] - The establishment of a new drug R&D platform in the Guangdong-Hong Kong-Macao Greater Bay Area and partnerships with top universities and research institutions have significantly strengthened the company's innovation capabilities [4] Investor Relations Management - The award for "Outstanding Investor Relations Management Team" underscores the company's commitment to building long-term, stable, and trustworthy relationships with investors [5] - Since its listing in 2017, Panlong Pharmaceutical has distributed a total of 133 million yuan in cash dividends, reflecting its governance philosophy that prioritizes shareholder interests [5] - The company has actively engaged in investor communication through multiple performance briefings and annual shareholder meetings, while also expanding online communication channels to ensure timely responses to investor concerns [5]